AMSTERDAM—Newly proposed systemic lupus erythematosus (SLE) classification criteria and new findings on SLE pathogenesis are two ways in which researchers and clinicians are getting a better grasp on the heterogeneous disease. The criteria and findings were discussed this June in a session at EULAR: the Annual European Congress of Rheumatology. ‘Paradigm Shift’ Sindhu Johnson, MD,…
AMSTERDAM—Low-grade inflammation in older adults can impede immune responsiveness, and researchers have shed light on how this happens. They have developed a short-term treatment that blocks inflammation and boosts the immune response, an expert said at EULAR: the Annual European Congress of Rheumatology. The findings were presented in a session on cellular senescence related to…
AMSTERDAM—Early identification and treatment of rheumatoid arthritis (RA) are two of the most pressing concerns in the field, an expert said at EULAR: the Annual European Congress of Rheumatology. He described the latest efforts to identify patients at risk of RA development and insights on quick referral to rheumatologists. Karim Raza, BM, BCh, PhD, Arthritis…
Sir William Osler, the father of modern medicine, said “the desire to take medicine is perhaps the greatest feature that separates man from animal.” Determination of the benefit of a medication can be challenging and includes a number of factors, such as pharmacologic activities on the disease pathophysiology, pharmacokinetic properties and patient characteristics.1,2 An additional,…
A study published in Annals of Internal Medicine in December 2017 looked at trends in lupus mortality over a 46-year period. The researchers say they set out to close some knowledge gaps. “There [was] a knowledge gap relating to the large differences we see in death rates from one study to another, which could have…
Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…
Studies highlighting the large numbers of people affected by knee osteoarthritis (OA) point to what clinicians who treat knee OA have been seeing for the past few decades: a substantial increase in the prevalence of knee OA in the U.S. and globally. Roughly 250 million people are affected by knee OA worldwide, and about 14…
The data tell the story. Despite improvements in overall outcomes for common rheumatologic conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), white patients fare better than minority patients, and sometimes substantially better. Even with new biologic therapies that have significantly altered the course of disease for patients with RA, outcomes for minorities…
A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…
More than two decades ago, Charles King, MD, was completing his final year of residency in internal medicine, fairly confident he was headed for a career in gastroenterology. Then he took a rotation in rheumatology. The rest, as they say, is history. “It’s a complicated field, and it requires a balance of left brained-ness and…